AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

MAP Microba Life Sciences Limited

Healthcare · Diagnostics & Research · website
$0.04
52wk 0.04 – 0.10
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Microba Life Sciences Limited

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$32.27M
P/E (trailing)
P/E (forward)
-4.93
EPS (trailing)
-0.04
Dividend yield
Payout ratio
0.0%
Beta
2.09
EV / EBITDA
-0.89
Price / Book
0.90
ROE
-60.0%
Operating margin
-149.0%
Net margin
-132.5%
Total cash
$11.27M
Total debt
$2.54M
Current ratio
1.73
Debt / Equity
0.08
Free cash flow
$-14.32M
Avg volume
713,559
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$15.67M
  • Gross profit$7.44M
  • Operating income-$24.61M
  • Net income-$14.94M
  • Diluted EPS-0.03
  • Free cash flow-$14.91M
  • Net debt-$8.51M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9